Clinical Trial Endpoints May Not Fit Real-World Studies
Symptom control, overall survival and time to treatment failure may be more useful measures in a real-world setting than progression-free survival, FDA oncology director Pazdur says.
Symptom control, overall survival and time to treatment failure may be more useful measures in a real-world setting than progression-free survival, FDA oncology director Pazdur says.